v3.26.1
Segments - Schedule of Segment Revenue and Expenses to Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Direct research and development expenses by program:    
Selling, general and administrative $ 16,169 $ 15,684
Interest income (2,570) (2,231)
Net loss (41,284) (35,907)
Operating Segments [Member]    
Direct research and development expenses by program:    
Personnel-related research and development [1] 8,994 8,358
Selling, general and administrative 16,169 15,684
Interest income (2,570) (2,231)
Other segment items [2] 75 335
Net loss (41,284) (35,907)
Operating Segments [Member] | Avexitide    
Direct research and development expenses by program:    
Total direct research and development expenses by program [3],[4] 9,990 5,426
Operating Segments [Member] | AMX0035 - PSP    
Direct research and development expenses by program:    
Total direct research and development expenses by program [3],[4] 649 4,563
Operating Segments [Member] | Other programs    
Direct research and development expenses by program:    
Total direct research and development expenses by program [5] $ 7,977 $ 3,772
[1] The Company does not allocate personnel and other similar costs to specific programs because these costs are deployed across multiple programs.
[2] Other segment items primarily consists of net realized and unrealized losses on foreign exchange transactions.
[3] Depreciation and amortization expense of $0.1 million during the three months ended March 31, 2026, and $0.2 million during the three months ended March 31, 2025, are allocated across the significant expense captions.
[4] The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. As the Company has one reportable segment, there were no intersegment eliminations for the three months ended March 31, 2026 and 2025.
[5] Other programs includes milestone payments totaling $4.0 million made to Gubra following the selection and handover of AMX0318 as a development candidate for PBH and other rare diseases during the three months ended March 31, 2026.